OS Therapies (NYSEAMERICAN:OSTX) Raised to Hold at Zacks Research

OS Therapies (NYSEAMERICAN:OSTX) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Separately, D. Boral Capital restated a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a research note on Friday, October 10th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $18.00.

OS Therapies Stock Up 1.6%

Shares of NYSEAMERICAN OSTX opened at $1.92 on Tuesday. The business’s 50 day moving average price is $2.01 and its two-hundred day moving average price is $1.90. The company has a market cap of $60.77 million, a PE ratio of -2.43 and a beta of -4.10. OS Therapies has a twelve month low of $1.12 and a twelve month high of $7.00.

Hedge Funds Weigh In On OS Therapies

Institutional investors and hedge funds have recently modified their holdings of the business. CM Management LLC increased its position in OS Therapies by 172.6% during the first quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $462,000 after acquiring an additional 189,956 shares during the period. XTX Topco Ltd bought a new stake in shares of OS Therapies in the second quarter valued at approximately $63,000. Bridgeway Capital Management LLC bought a new stake in shares of OS Therapies in the second quarter valued at approximately $47,000. Finally, Ground Swell Capital LLC acquired a new stake in OS Therapies during the third quarter worth approximately $40,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.